

## LivaNova Welcomes William Kozy to Board of Directors

**London, June 13, 2018** – LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, today announced that William A. Kozy, retired Executive Vice President and Chief Operating Officer at Becton, Dickinson and Company (“BD”), was elected by the Company’s shareholders to its board of directors during its June 12 annual general meeting.

“Bill brings extensive board and healthcare experience to LivaNova from his career of more than 40 years in the global medical technology industry. He is a revered business leader and a valuable addition to our board,” said Daniel J. Moore, LivaNova Chairman of the Board. “Bill has a wealth of management experience and broad knowledge of global strategy, manufacturing, M&A and product development—all relevant to our business.”

Kozy joined BD in 1974 and was ultimately responsible for all worldwide businesses of the company, with a specific focus on profitable revenue growth and talent development. He held several senior executive positions within the company, including president of BD Diagnostics from 2003 to 2006.

“Bill joins LivaNova at an exciting time,” said Damien McDonald, LivaNova Chief Executive Officer. “His insight, judgment and global perspective will add value to the board as we continue to transform our business. We look forward to his contributions.”

### About LivaNova

LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. LivaNova’s advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems. Headquartered in London, LivaNova has a presence in more than 100 countries worldwide. The Company currently employs more than 3,500 employees. LivaNova operates as two businesses: Cardiac Surgery and Neuromodulation, with operating headquarters in Mirandola (Italy) and Houston (U.S.A.), respectively.

**For more information, please visit [www.livanova.com](http://www.livanova.com).**

### Safe Harbor Statement

This news release contains forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Forward-looking statements are not historical facts but are based on certain assumptions of management and describe LivaNova's future plans, strategies and expectations. Forward-looking statements can generally be identified by the use of forward-looking terminology, including, but not limited to, "may," "could," "seek," "guidance," "predict," "potential," "likely," "believe," "will," "expect," "anticipate," "estimate," "plan," "intend," "forecast," or variations of these terms and similar expressions, or the negative of these terms or similar expressions. Forward-looking statements contained in this news release are based on information presently available to LivaNova and assumptions that LivaNova believes to be reasonable, but are inherently uncertain. As a result, LivaNova's actual results, performance or achievements may differ materially from those expressed or implied by these forward-looking statements, which are not guarantees of future performance or actions that may be taken by LivaNova and involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond LivaNova's control. You should carefully consider the risks and uncertainties that affect LivaNova, including those described in the "Risk Factors" section of LivaNova's Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other documents filed from time to time with the United States Securities and Exchange Commission.

All information in this news release is as of the date of its release. LivaNova does not undertake or assume any obligation to update publicly any of the forward-looking statements in this news release to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable law. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. We caution you not to place undue reliance on any forward-looking statements, which are made only as of the date of this news release.

### **LivaNova PLC Investor Relations and Media**

**Karen King**, +1 281-228-7262

Vice President, Investor Relations & Corporate Communications

**Deanna Wilke**, +1 281-727-2764

Director, Corporate Communications – Products & Therapies

[corporate.communications@livanova.com](mailto:corporate.communications@livanova.com)

###